Abstract Upon HIV infection, a subset of latently infected cells carrying transcriptionally inactive integrated proviral DNA (the HIV-1 reservoir) is rapidly established. These cells are the main force behind HIV persistence under highly active antiretroviral therapy (HAART), which only impacts on actively replicating viruses and it is therefore unable to eradicate the infection. However, the case of Timothy Brown, also known as the Berlin patient, demonstrates that eradication is possible, and recent data support the idea that latency may be reverted in vivo, suggesting that it is possible to perturb the HIV-1 reservoir. This may be achieved by implementing both pharmacological and immunological strategies to reactivate HIV-1 from latently infected cells. Nevertheless, reactivation might not be sufficient to eradicate the virus. Reinforcing HIV-1-specific immune responses and blocking potential new events of viral replication will probably help reaching the final goal of eradication or the alternative objective of a functional cure for HIV-1.
Introduction
Highly Active Antiviral Therapy (HAART) is extremely effective at restricting active human immunodeficiency virus (HIV) replication and it is able to sustain suppression of plasma viremia below the limit of detection of standard assays [1] . However, viremia rapidly resumes if therapy is interrupted. Our current inability to therapeutically eradicate HIV, despite prolonged suppression of plasma viremia, is ultimately related to the intrinsic stability of the integrated virus genome in the chromosome of infected cells [2] [3] [4] . When this integration occurs in long-lived cells, such as resting memory CD4+ T cells, a persistent latent reservoir is established preventing the clearance of the virus with the existing therapeutic options [5] [6] [7] . Consequently, HIV infected individuals must commit to expensive, life-long therapies and must tackle problems associated with uninterrupted HAART and chronic infection, including continuous clinical monitoring (for CD4 counts and viral load), drug toxicities and chronic immune activation/inflammation, globally resulting in increased incidence of co-morbidities and mortality compared with non-infected individuals [8] . The complex management of long-term treatment in HIVinfected subjects has generated interest in developing new strategies for HIV therapy, aimed at increasing survival and reducing drug toxicities, including treatment simplifications, structured treatment interruptions (STI), and development of new antiretroviral drugs. While the former strategy is under debate, the use of STI has been ruled out by the compelling data of the SMART study [9] , and the development of new drugs has improved the safety profile of current HAART regimens, that are still unable to impact on latently infected cells. Therefore, there is an emergent interest in developing safe and affordable curative strategies that would eliminate the need of lifelong therapy while improving the health of infected subjects, and reducing the risk of viral transmission to uninfected individuals [10] .
Two potential models of HIV cure have been pursued until now. First, a sterilizing cure, which aims at purging the virus and totally eliminating all HIV-infected cells from any cellular or anatomical compartment in an infected individual. The most famous (and unique) example is the case-report of Timothy Brown, also known as the Berlin patient, who became undetectable for HIV after an allogeneic bone marrow transplant from a homozygous CCR5Δ32 donor [11, 12•] . An alternative to this desirable, but not universally affordable, eradication strategy would aim at reaching a functional cure, where immunotherapeutic approaches would allow for a persistent control of viral replication without any antiretroviral treatment. This functional cure aims at mimicking the situation encountered in elite controllers and post-treatment controllers [13, 14] and subsequently, it may be effective by stopping the HIV transmission to those who are uninfected, and by restoring immunological function and normal health to those who are infected. Nevertheless, some elite controllers show residual viremia and higher immune activation than uninfected individuals [15] , being potentially at risk of developing more non-AIDS events than HIV-free individuals.
Establishment of the Latent Reservoir
HIV eradication and functional cure will require the elimination or the reduction of the HIV reservoir size. Therefore, understanding the establishment and cellular distribution of latently infected cells is a major need to reduce HIV reservoirs. The primary mechanism for the establishment of latency is probably due to the infection of highly susceptible activated memory CD4+ T cells. Most of these cells die by the cytopathic effect of the virus [16] , but a minority may revert to a resting state by the effect of immunomodulatory cytokines (IL-10, TGF-β, IL-1RA) [17, 18] , thereby silencing viral transcription and creating the memory HIV reservoir. IL-7 and IL-15 cytokines promote the survival of latently infected cells; therefore this latent state is extremely stable and it is limited only by the lifespan of the infected cell and its progeny. Alternatively, infection might happen directly in quiescent CD4+ T cells (antigen experienced or naïve), where HIV may integrate in the absence of cell activation [19] . However, resting CD4+ T cells are considered to be resistant to HIV infection in vitro compared with activated cells [20] .
Irrespective of the mechanism, the pool of latently infected cells harboring replication competent virus is established very early in infection [21, 22] , and it has been suggested that nadir CD4+ T-cell values might predict the size of this reservoir [23] . Indeed, the HIV infection might create the environment of cytokines necessary for the establishment of latently infected cells. The initial burst of inflammatory cytokines during the acute phase of the infection might favor the infection of activated cells, followed by the anti-inflammatory/immunosuppressive response of the chronic phase, which might promote the generation of quiescent memory cells harboring integrated HIV DNA. Therefore, early initiation of treatment would be important not only for preserving immune functions but also for reducing the size of the latent reservoir [24] .
Maintenance of HIV Reservoir: the Mechanisms of HIV Persistence
Multiple mechanisms, not mutually exclusive, are likely to contribute to HIV persistence in HAART-treated subjects. All CD4+ T-cell subsets (naïve, central memory, transitional memory and effector memory) have been shown to contain integrated viral DNA during long-term infection [25•] . However, the specific biological features of each subset may impact in the maintenance of the latent reservoir, due to their differential lifespan, response to stimuli and proliferation capacity. Since the size of the latent reservoir is relatively stable [26] and T-cell diversity becomes more homogeneous over time [27] , it is tempting to suggest that HIV persistence is maintained by the long-lived and proliferating latently infected pool of CD4+ T cells [26, 28, 29] . Indeed, HIV primarily persists in the central and transitional memory compartments of CD4+ T cells, which are maintained through Tcell survival and low-level antigen-driven proliferation, and homeostatic proliferation, respectively [25•] .
The existence of residual viral replication (de novo infection of target cells) could play also a role in the continuous replenishment of the latent reservoir [3, 30, 31•, 32, 33] . Indeed, specific anatomical compartments such as gut mucosa, genital tract, lymph nodes and central nervous system are enriched in HIV-infected cells [34] [35] [36] [37] [38] . This observation may be related with a suboptimal penetration of standard treatments compared with periphery [39] [40] [41] and the high CD4+ T-cell density in these tissues that may favor cell-to-cell HIV transmission, which in turn may have lower sensitivity to HAART inhibition [42] . Other longlived reservoirs of non-T-cell populations -such as macrophages, hematopoietic stem cells, dendritic cells, thymocytes or astrocytes [43, 44] -, and the failure of an HIVspecific immunity to recognize and eliminate infected cells might also constitute alternative factors contributing to the persistence of the latent reservoir.
Interestingly, both mechanisms of HIV persistence may be modulated by inflammation and immune activation, widely described in HAART treated patients. Homeostatic proliferation is strongly dependent on IL-7 whose levels increase in HIV infected individuals as CD4 T-cell counts are lost. Similarly, inflammatory cytokines, and the general status of activation of CD4+ T cells, that also strongly associates with CD4+ T-cell decay, may modulate reactivation of latently infected cells and may sensitize target cells for new cycles of infection. However, the complex interplay between inflammation and control of the HIV reservoirs remains largely unknown.
Measurement of HIV Persistence
One of the main problems that limit our knowledge in HIV reservoir and HIV persistence is our inability to precisely measure its size. Several assays have been used routinely to quantify HIV persistence and to detect latently infected cells, in order to measure the efficacy of interventions aimed at reducing the viral reservoirs. These assays include measurements of RNA or DNA formed during HIV life cycle. The first category includes the ultrasensitive measurement of plasma HIV RNA (or single copy assay) [45] , which is used to detect potential infectious viral particles; however, non-replicative, uninfectious virions are also quantified with this technique. In additionally, it is possible to measure cell-associated RNA, extracellular or cell-associated unspliced and multiply spliced RNA; the latter forms measure HIV transcription in productively and reactivated latently infected cells [46, 47] . Regarding DNA forms, integrated HIV DNA or the ratio of nonintegrated to integrated DNA levels could also account to measure HIV persistence, as well as episomal DNA (including 2-LTR circles), which is a remaining form of unintegrated HIV DNA. In patients on HAART, the majority of HIV DNA consists of integrated proviral DNA in resting CD4+ T cells [48] that can be measured by an Alu-LTR PCR [49] . However these assays are complex and also measure integrated proviral DNA with unknown potential for reactivation. Episomal DNA circles, which are produced upon de novo cell infection, have shown controversy regarding their stability in the cell [50, 51] . Therefore, they can be considered as a surrogate marker of recent infection if they have a short half-life; conversely, if they are stable, they might measure latently infected cells. Finally, it is also possible to measure the frequency of CD4+ T cells carrying latent but replication-competent virus in outgrowth cultures [26] . The major limitations of using this technique is the need for large blood volumes and its wide coefficient of variation [52] . Despite all these assays to measure HIV persistence, the relationships between these measurements and the amounts of latent virus and the degree of persistent cryptic replication remain uncertain. More sensitive methods, such as digital droplet PCR [53] , and more comprehensive analysis that help in the interpretation of data is clearly needed for the study of HIV reservoirs.
Targeting the HIV reservoir

Using our Current Weapons: HAART Optimization and/or Intensification
Residual viral replication during suppressive-HAART constitutes a potential mechanism for HIV persistence, which might favor the persistent levels of immune activation and the incomplete restoration of the CD4+ T-cell compartment [33, 54] . The aim of the HAART intensification strategy is to eliminate all residual viral replication that might occur in anatomical and/or cellular sanctuaries with low drug penetration (Fig. 1) . The intensification of HAART with antiretroviral drugs with new mechanisms of action, such the integrase inhibitor raltegravir, has been used to test this hypothesis. Several studies on HAART-treated subjects were able to detect changes in markers of persistent viral replication (2-LTR circles, unspliced RNA in CD4+ T cells or latent replication competent viruses), concomitantly with a reduction in immune activation [31•, 34, 55, 56] . These results suggest new cycles of HIV infection, which might contribute to a slow, but continuous, replenishment of viral reservoirs in the face of HAART. However, other studies (with different sample size, intensification periods, methodology and sampling frequencies) did not confirm these results [57] [58] [59] [60] . Most studies have looked at the effect of raltegravir-intensification on residual viremia in plasma, with negative results [31•, 32, 55, 58, 60-62] . Overall, these results suggest that residual plasma viremia might reflect the production of viral particles from the latent reservoir following reactivation rather than ongoing viral replication. Furthermore, if persistent immune activation in HAARTtreated subjects is exclusively driven by virus being released from the latent reservoir, HAART intensification through addition of another antiretroviral agent should have no impact on activation markers. The reported decreases in immune activation during intensification of HAART seem to link immune activation and residual viral replication.
Reversal of HIV Latency
HIV-1 proviruses are strongly suppressed under an epigenetic environment caused by chromatin modifications, like histone acetylation and DNA methylation. Therefore, inhibitors targeting histone deacetylases (HDAC), histone methyltransferase (HMT) and DNA methyltransferase are good candidates to reactivate latently infected-cells (Fig. 1) . In fact, a switch from latent to active transcription has been described following treatment with several HDAC inhibitors such as valproic acid, vorinostat, among others [63] [64] [65] [66] [67] [68] . Studies with valproic acid did not consistently demonstrate in vivo a marked depletion of resting cell infection in patients on HAART [69] [70] [71] [72] [73] , theoretically due to their ineffectiveness in inhibiting HDAC3 activity in CD4+ T cells [74] . In contrast, a recent pilot clinical trial using the more potent HDAC inhibitor vorinostat (or SAHA) has shown an in vivo reactivation of HIV latency in patients on HAART [75•] . Indeed, vorinostat is able to activate PI3K/Akt pathway in primary memory CD4+ T cells, recruiting the positive transcription factor-b (P-TEFb) to the LTR, which can then induce viral transcription [65] . These encouraging results constitute a proof-of-concept that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans. However, its real efficacy at reducing HIV reservoir is unknown as the reported effect did not translate into changes in plasma viremia or in the viral reservoir measured in resting CD4+ T cells [75•] .
The HMTs Suv39H1 and G9a have been demonstrated to play a role in HIV-1 transcriptional silencing in vitro [76] , and specific inhibitors of HMT, chaetocin and BIX-01294 respectively, used alone or in combination with other HIV-1 inducers cause HIV reactivation in resting memory CD4+ T cells from HAART-treated patients with a higher extent than other HIV inducers [77] . However, these compounds cannot be safely administrated to humans and further investigation in HMT inhibitors should be pursued. In the same direction, DNA methyltransferases inhibitors, such as 5-azacytidine, should be further investigated by its ability to enhance reactivation and outgrowth of silenced provirus in vitro [78, 79] . Purging the latent reservoir could also be achieved by inhibiting regulatory processes that prevent reactivation. For instance, hexamethylene bisacetamide (HMBA) compounds can transiently activate HIV transcription in primary infected cells via release of p-TEFb, and also lead to cellular differentiation and apoptosis of the cells [80] . Compounds related to HMBA have now been approved for clinical use and could be tested to eliminate the reservoir of HIV.
In addition to epigenetic silencing, HIV transcription initiation factors, such as NF-κB and NFAT, are sequestered in the cytoplasm, while the essential Tat cofactor, P-TEFb, is largely sequestrated into an inactive ribonucleoprotein complex, ensuring that latent proviruses remain transcriptionally silenced for long periods. However, NF-κB promotes global T-cell activation running the risk of systemic inflammatory response in patients. Therefore, NF-κB activators safer than PMA or TNF-α, such as prostatin, bryostatin are being investigated [65, 81, 82] . The in vitro combination of prostratin and SAHA overcomes the limitations of single-agent approaches and can act synergistically to efficiently reactivate many HIV-1 subtypes [82] .
Another interesting compound is disulfiram, used to treat alcoholism by inhibiting aldehyde dehydrogenase, and has shown to reactivate HIV-1 gene expression in an in vitro primary cell model of HIV-1 latency [83] . However, a small pilot project administrating disulfiram to HIV infected subjects did not show any reduction in the size of the latent reservoir [84] . A recent screening from a library of compounds identified a group of quinolin-8-ol derivatives that can induce the latent HIV reservoir in vitro without T-cell activation, expanding the number of latency reversing agents [85] . For future studies, it is not only important to expand the number of latency reversing agents, but also the development of new technologies to improve the delivery systems of these compounds into the target cells. For instance, nanotechnology (such as lipid nanoparticles) provide a better drug solubility, stability and the capacity to simultaneously target multiple different molecules to particular cell or tissue types and therefore, might improve the current methods for activating the latent reservoir [81] .
Immune-Based Therapies
Another strategy, known as immune activation therapy, aims at eliminating the reservoir by reactivating latently infected memory CD4+ T cells and by increasing the turnover rate of the latent viral reservoir to expose them to removal by cytotoxic immune responses (Fig. 1) . Several cytokines, including IL-2, IL-7, IL-15 and IL-21, which share a common γ-chain, might have putative roles in improving control of HIV-1 infection, being IL-2 the best studied cytokine in this setting. In the SILCAAT and the ESPRIT trials, induction and maintenance cycles of recombinant human IL-2 (rhil-2) were added to suppressive HAART and produced a significant CD4+ Tcell expansion without an increase in viral load [86, 87] . Despite these encouraging results, the rate of opportunistic infections or death was not statistically different from the HAART group and the effects of this combination on purging viral reservoirs was unclear [88, 89] . Taking all together, adjunctive IL-2 administration has limited effects, showing no significant improvement compared with HAART alone.
Another interesting cytokine is IL-7 that is essential for the maintenance of T-cell homeostasis, by enhancing mature Tcell survival and expansion of both peripheral CD4+ and CD8 + T cells. Indeed, IL-7 can reactivate HIV in latently infected cells in vitro in the absence of viral reactivation or cell differentiation of latently infected cells [90] [91] [92] . In additionally, CD4+ T cells isolated from virally suppressed subjects proliferate in response to IL-7 stimulation, maintaining the HIV reservoir in its size and genetic diversity [25•] . Several clinical trials administrating IL-7 on subjects with a good (ACGT 5214) or poor (eudract study −2004-003772-11A) immunological response to suppressive HAART have showed similar results: significant expansion of circulating central memory (but also naïve) CD4+ and CD8+ T cells; however, some patients (especially ones in higher dose groups) experienced several blips in plasma viremia during the treatment period [93] [94] [95] . Likewise, a clinical trial administrating IL-7 coupled with antiretroviral drugs is currently ongoing to test its ability to reduce the HIV reservoir (ERAMUNE-1).
In the same direction, IL-15 has been shown to induce viral reactivation in vitro as a consequence of differentiation of memory CD4+ T cells with a minimal effect on proliferation [92] , showing some advantages over IL-2. However, IL-15 treatment in combination with antiretroviral therapy in chronically simian immunodeficiency virus (SIV)-infected rhesus macaques delayed viral suppression, and was only able to induce a transient proliferation on memory CD8+ T cells but not in CD4+ T cells; moreover, IL-15 treated animals experienced faster loses of CD4+ T cells after HAART interruption than those receiving antiretroviral therapy alone [96] . Therefore, IL-15 should be further studied before considering it as a possible candidate to deplete the latent HIV reservoir.
Another cytokine that can be potentially used for immunotherapeutic trials is IL-21, which is able to induce a potent upregulation of the cytotoxic effector in CD8+ T cells promoting antiviral activity in absence of cellular proliferation or activation and without inducing HIV-1 replication in vitro [97] . Indeed, the administration of IL-21 to chronically SIVinfected viremic animals could augment the cytotoxic potential of T cells and NK cells, and promote B cell differentiation with increases in SIV antibody titers without an increase in cellular activation [98] . Recent findings pointed out that IL-21 treatment during acute SIV infection beneficially impacts not only peripheral but also intestinal immunity, increasing homeostasis of Th17 cells, reducing levels of T-cell activation and limiting microbial translocation without undesirable effects on viral load [99] . Therefore, IL-21 should be further explored as a potential immune modulator to be used as an adjuvant to HAART in HIV infected subjects.
A second attractive immunological target is PD-1. This inhibitory molecule, which is up-regulated in HIV-specific CD4+ and CD8+ T cells, has recently emerged as a potential target to facilitate HIV eradication. Within the memory CD4+ T-cell compartment, cells expressing high levels of PD-1 contain more proviral HIV DNA than PD-1 low cells [25•] , and cell-associated RNA levels are associated with the frequency of PD-1 expressing CD4+ T cells. Additional studies suggest that blocking PD-1 triggers HIV replication and might therefore reactivate latent virus, giving the opportunity to the body to eliminate the resulting productively infected cells by cell death and/or clearance of HIV-specific immune response [100] . Recent studies in rhesus macaques showed beneficial effects of PD-1 blockade using an antibody to PD-1 during chronic SIV infection [101, 102] . There was a rapid expansion of virus-specific CD8+ T cells with improved functional quality (in blood and gut) and a proliferation of memory B cells with increased production of SIV envelope-specific antibodies. These improved immune responses were associated with significant reductions in plasma viral load and also prolonged the survival of SIV-infected macaques [101] . Moreover, PD-1 blockade reduced persistent immune activation and bacterial translocation [102] . These results suggest that PD-1 blockade could be used in combination with HAART to enhance immune system recovery and as a strategy to reactivate the latent reservoir in HIV infected subjects. Currently, the ACTG 5301 is testing if the inhibition of PD-1 with a specific antibody activates in a relatively specific manner cells containing HIV, while simultaneously causing enhancement of HIV-specific immunity.
Therapeutic Vaccination
Elite controllers and post-treatment controllers are characterized by an effective HIV-specific CD8+ T-cell response, including a recognition with high avidity and/or cross reactivity against conserved epitopes in Gag, a production of multiple cytokines (multifunctional) and a preserved proliferative capacity. Importantly, the qualitative features most closely associated with immunologic control of HIV are related to the ability of HIV-specific CD8+ T cells to increase their contents in cytotoxic proteins, which mediate elimination of HIVinfected CD4+ T cells [103] . These results in elite controllers provide a rationale to attempt the development of strategies to enhance host immune control by therapeutic vaccines (Fig. 1) . Interestingly, the development of a rhesus cytomegalovirus (CMV)-based vaccine for SIV showed control of a mucosal challenge with SIV, prevented virus dissemination and led to the clearance of SIV with time [104] by inducing the development of large populations of effector memory CD8+ T cells [105] , which respond rapidly to an antigenic challenge. Other approaches such as DC-based vaccines have also been tested with modest but promising results [106] . Thus, therapeutic vaccines provide a powerful new approach for HIV control, preventing relapse and, perhaps, ultimately clearing residual infection.
The role of immune control has been highlighted recently. Several strategies aim at reverting latency during HAART assume that infected cells will die after virus reactivation. However, a recent study shows that after reversal of latency in an in vitro model using vorinostat, infected resting CD4+ T cells survived despite viral cytopathic effects, even in the presence of autologous cytolytic T lymphocytes (CTL) from most patients on HAART [107•] . Only the presence of autologous CTLs in elite controllers or prestimulation of patient CD8+ T cells led to elimination of HIV-1 latently infected cells. Therefore, boosting HIV-specific CTL responses prior to reactivating latent HIV-1 may be essential for successful eradication efforts.
Conclusions
HIV persistence appears to be the main roadblock to HIV eradication or to achieve a functional cure. Probably, a combination therapy using multiple drugs or immune modulators synergistically acting at different latency checkpoints will have to be used in order to purge the different compartments of the viral reservoir (Fig. 1) [65, 67, 77] . However, it is unclear whether this strategy alone will be successful.
Certainly, the potential requirement of a rapid killing of reactivated cells and the need of a complete inhibition of new replication events will add complexity to the cure strategy, but may increase the success rate. We are just starting the path towards eradication, and we have to carefully evaluate reactivation strategies, either immunological or pharmacological, as other ancestral retroviral sequences present in the human genome may become upregulated [108] . Moreover, to increase HIV control, effective therapeutic vaccination and HAART optimization should be pursuit in parallel. The intersection of these research pathways will open wider avenues for HIV eradication.
